Biocon Biologics Integrates Viatris' Biosimilar Biz in Europe
By Rediff Money Desk, NEWDELHI Nov 30, 2023 16:46
Biocon Biologics completes integration of Viatris' biosimilar business in 31 European countries, expanding access to lifesaving treatments.
![Biocon Biologics Integrates Viatris' Biosimilar Biz in Europe](https://im.rediff.com/money/2023/nov/24biocon-biologics.jpg)
Photograph: Kind courtesy Biocon Biologics/Facebook
New Delhi, Nov 30 (PTI) Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European countries.
Following the deal closure in November 2022, the company, a unit of Biocon Ltd, had earlier announced the integration of Viatris Inc's business in over 70 countries in emerging markets, effective July 1, 2023, and North America in September 2023.
"The integration of the Viatris biosimilar business in Europe ahead of schedule is another important milestone for Biocon Biologics in our journey as a global biosimilar leader. We are pleased to expand access to lifesaving treatments for patients across Europe," Biocon Biologics CEO and MD Shreehas Tambe said in a statement.
The pipeline of 20 products will allow the company to better address patient needs and be a reliable partner to health organisations, he added.
Biocon Biologics and its partners will commercialise biosimilar products in various European countries like Albania, Austria, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Greece, Switzerland, and the United Kingdom, the company said.
In February last year, Biocon Biologics inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.33 billion.
Following the deal closure in November 2022, the company, a unit of Biocon Ltd, had earlier announced the integration of Viatris Inc's business in over 70 countries in emerging markets, effective July 1, 2023, and North America in September 2023.
"The integration of the Viatris biosimilar business in Europe ahead of schedule is another important milestone for Biocon Biologics in our journey as a global biosimilar leader. We are pleased to expand access to lifesaving treatments for patients across Europe," Biocon Biologics CEO and MD Shreehas Tambe said in a statement.
The pipeline of 20 products will allow the company to better address patient needs and be a reliable partner to health organisations, he added.
Biocon Biologics and its partners will commercialise biosimilar products in various European countries like Albania, Austria, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Greece, Switzerland, and the United Kingdom, the company said.
In February last year, Biocon Biologics inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.33 billion.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![SBI 444-Day Term...](https://im.rediff.com/80-80/money/2017/aug/01bank.jpg)
SBI 444-Day Term Deposit: Up to 7.25% Annual...
State Bank of India launches a 444-day term deposit offering up to 7.25% annual...
![India To Set Up...](https://im.rediff.com/80-80/money/2020/sep/15business-2.jpg)
India To Set Up Centre For Trade Negotiation...
India's Commerce Ministry plans to establish a centre for negotiation skills to...
![Vi Improves...](https://im.rediff.com/80-80/money/2024/may/14may-vi.jpg)
Vi Improves Network Coverage in Uttarakhand & UP
Vi expands L900 & L2100 technologies in UP and Uttarakhand, offering improved indoor...